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IMPORTANCE Cerebral microbleeds (CMBs) have been established as an independent
predictor of cerebral bleeding. There are contradictory data regarding the potential
association of CMB burden with the risk of symptomatic intracerebral hemorrhage (sICH) in
patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT).
OBJECTIVE To investigate the association of high CMB burden (>10 CMBs on a pre-IVT
magnetic image resonance [MRI] scan) with the risk of sICH following IVT for AIS.
DATA SOURCES Eligible studies were identified by searchingMedline and Scopus databases.
No language or other restrictions were imposed. The literature search was conducted on
October 7, 2015. This meta-analysis has adopted the Preferred Reporting Items for Systematic
Reviews andMeta-Analyses (PRISMA) guidelines and was written according to the
Meta-analysis of Observational Studies in Epidemiology (MOOSE) proposal.
STUDY SELECTION Eligible prospective study protocols that reported sICH rates in patients
with AIS who underwent MRI for CMB screening prior to IVT.
DATA EXTRACTION AND SYNTHESIS The reported rates of sICH complicating IVT in patientswith
AISwith pretreatmentMRIwere extracted independently for groups of patients with 0 CMBs
(CMB absence), 1 ormore CMBs (CMBpresence), 1 to 10 CMBs (low tomoderate CMBburden),
andmore than 10 CMBs (high CMBburden). An individual-patient datameta-analysis was also
performed in the included studies that provided complete patient data sets.
MAIN OUTCOMES ANDMEASURES Symptomatic intracerebral hemorrhage based on the
European Cooperative Acute Stroke Study–II definition (any intracranial bleed with4 points
worsening on the National Institutes of Health Stroke Scale score).
RESULTS We included 9 studies comprising 2479 patients with AIS. The risk of sICH after IVT
was found to be higher in patients with evidence of CMB presence, compared with patients
without CMBs (risk ratio [RR], 2.36; 95% CI, 1.21-4.61; P = .01). A higher risk for sICH after IVT
was detected in patients with high CMB burden (>10 CMBs) when compared with patients
with 0 to 10 CMBs (RR, 12.10; 95% CI, 4.36-33.57; P < .001) or 1 to 10 CMBs (RR, 7.01; 95% CI,
3.20-15.38; P < .001) on pretreatment MRI. In the individual-patient data meta-analysis, high
CMB burden was associated with increased likelihood of sICH before (unadjusted odds ratio,
31.06; 95% CI, 7.12-135.44; P < .001) and after (adjusted odds ratio, 18.17; 95% CI, 2.39-138.22;
P = .005) adjusting for potential confounders.
CONCLUSIONS AND RELEVANCE Presence of CMBandhigh CMBburdens onpretreatmentMRI
were independently associatedwith sICH in patientswith AIS treatedwith IVT. High CMBburden
may be included in individual risk stratification scores predicting sICH risk following IVT for AIS.
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C erebral microbleeds (CMBs) as visualized on gradientecho T2* or susceptibility-weighted magnetic reso-nance imaging (MRI) are consideredmarkers of bleed-
ing-prone cerebral vessel microangiopathies and constitute
both significant and independent predictors of future cere-
bral bleeding.1-3 Several clinical studies have associated CMB
presence with hemorrhagic stroke and hemorrhagic compli-
cations following antithrombotic medications.4
The potential association of CMB presence with the risk
of symptomatic intracerebral hemorrhage (sICH) in patients
with acute ischemic stroke (AIS) treated with intravenous
thrombolysis (IVT) remains controversial.5-7Moreover, the re-
lationship of CMBburdenwith an increased risk of sICH com-
plicating IVT for AIS remains to be determined.5,6 A previous
comprehensivemeta-analysis5 that has attempted to system-
atically evaluate this specific research question has included
patients with AIS treated both with intravenous and intra-
arterial reperfusion therapies including mechanical throm-
bectomy.However, this implies inclusionof a relevant patient
group that has received no thrombolytic agent and inclusion
ofpatients receivingboth intravenousand intra-arterial throm-
bolytic therapy.5Notably, in thismeta-analysis, highCMBbur-
den (definedas>10CMB)wasassociatedwithanexcessive risk
ofsICH.5Moreover, theothermeta-analysisonthetopic6evalu-
ated the risk of sICH in the presence of CMBs in patients with
AIS treatedwith systemic thrombolysis without investigating
the effect of CMB burden (stratified according to CMB
number) on the risk of sICH.6
In view of these considerations, we conducted a system-
atic review and meta-analysis of individual patient data and
sought to investigate theassociationofCMBpresence (≥1CMB
vs 0 CMB) and CMB burden (>10 CMBs vs 1-10 CMBs) on pre-
treatmentMRIwithsICHrisk,usingall availabledata frompro-
spective observational studies including patients with AIS
treated solely with systemic thrombolysis.
Methods
Trial Identification and Data Abstraction
Thismeta-analysis has adopted thePreferredReporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines8 and was written according to the Meta-analysis of
ObservationalStudies inEpidemiology (MOOSE)proposal.9Eli-
gible prospective study protocols reporting rates of sICH af-
ter IVT inpatientswhounderwentCMBscreeningprior to the
administrationof IVTwere identifiedbysearchingMedlineand
Scopus. The combinationof search strings thatwasused in all
database searches included the terms cerebral microbleeds,
intravenous thrombolysis, alteplase, and tissue plasminogen
activator.No languageorother restrictionswere imposed.The
literature searchwas conducted onOctober 7, 2015. The com-
plete search algorithm that was used in theMedline search is
available in the eMethods in the Supplement. Reference lists
of all articles thatmet our inclusion criteria andof relevant re-
viewarticleswere examined to identify studies thatmayhave
beenmissed by the initial database search. All retrieved stud-
ies were scanned independently by 2 reviewers (G.T. and
A.H.K.). In caseofdisagreement regarding the literature search
results between the aforementioned 2 authors, a third coau-
thor (R.Z.)wasconsulted, anddisagreementwas resolvedwith
consensus.We also included available data fromapilot study
thatwas performed in our institutiononwhether the feasibil-
ity of MRI screening for stroke mimics identification among
patients with AIS eligible for IVT administration.10
The outcome event of interest was sICH that was ascer-
tained using standard definitions combining neuroimaging
and/or autopsy informationwith clinical evidence of deterio-
ration on neurological examination.6,7 The reported rates of
sICH after IVT in patients with AIS undergoing CMB screen-
ing prior to alteplase administrationwere extracted indepen-
dently by the 2 authors who performed the literature search
(A.H.K. and G.T.) for the following subgroups of patients:
(1) CMBabsence (noCMBsonpre-IVTMRI), (2) CMBpresence
(1 or more CMBs on pre-IVT MRI), (3) low/moderate CMB
burden (1-10CMBsonpre-IVTMRI), and (4) highCMBburden
(>10 CMBs on pre-IVT MRI).
The cutoff of CMBs todefinehighmicrobleedburdenwas
selected a priori based on the findings of a previous meta-
analysis5 that also suggested an excess risk of sICH in pa-
tients with more than 10 CMBs, but the study had low statis-
tical power owing to the lownumber (n = 7) of patientswith a
CMB count of more than 10 included5 and the corresponding
wide confidence intervals. Cerebral microbleeds were de-
finedas small (generally 2-5mmindiameterbutup to 10mm),
hypointense,homogenous, round,oroval lesions thatwerevis-
ible on T2*-weighted gradient-recalled echo (GRE) or suscep-
tibility-weightedsequence imaging (SWI)andnot seenoncom-
puted tomography or on fluid-attenuated inversion recovery,
T1-weighted,orT2-weightedsequences.11 In those studiespro-
viding sufficientdata, the corresponding risk ratios (RRs)were
calculated to express the relative risk of sICH after IVT in AIS
between patients with CMB presence and CMB absence and
the relative risk of sICHafter IVT inAIS betweenpatientswith
low/moderate CMB presence and high CMB burden. For the
purposeof ourmeta-analysis,we also contacted all authors of
eligible studies toprovide complementary, nonpublisheddata
regarding sICH in the 4 prespecified CMB subgroups.
Key Points
Question What is the association of high cerebral microbleed
(CMB) burden (>10 CMBs) with the risk of symptomatic
intracerebral hemorrhage following intravenous thrombolysis in
patients with acute ischemic stroke?
Findings In this meta-analysis, higher risk for symptomatic
intracerebral hemorrhage after intravenous thrombolysis was
detected in patients with high CMB burden when compared with
patients with 0 to 10 or 1 to 10 CMBs on pretreatment magnetic
resonance imaging. High CMB burden was associated with
increased likelihood of symptomatic intracerebral hemorrhage
before and after adjusting for potential confounders.
Meaning High CMB burden on pretreatment magnetic resonance
imaging is independently associated with symptomatic
intracerebral hemorrhage in patients with acute ischemic stroke
treated with intravenous thrombolysis.
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After the overall analyses regarding the number of CMBs
on pre-IVTMRI, we performed additional subgroup analyses
using themagnetic resonance sequence formicrobleeddetec-
tion (GRE vs SWI) and the field strength of theMRI scan (1.5 T
vs 3.0 T) as potential confounders both in individual-patient
data meta-analysis and in the pairwise meta-analysis.
Meta-analysis of Individual-Patient Data
We attempted to capture the individual-patient data regard-
ing the association of CMB number on pretreatmentMRI and
risk of sICH in patients with AIS treated with IVT by directly
contacting the corresponding authors of all studies that were
included in the initial pairwise meta-analysis. We confirmed
all data that had been received for all appropriate individuals
by checking that the numbers supplied were consistent with
theoriginal publications and thatnoobviousomissionsordu-
plicates in the sequence of patient record or study identifier
numberswerepresent.12 Finally, data suppliedwere either re-
codedor transformed to reflect commondefinitions (eg, sICH
definition) and common units of measurement (eg, serum
glucose) across the generated individual-patient database.
Statistical Analyses
ExtractedRRs from the included studyprotocolswerepooled
separatelyusingtherandom-effectsmodel (DerSimonianLaird)
owingtothepresumedheterogeneitybetweenindividualstudy
estimates.Theequivalent z testwasperformedforeachpooled
RR, and a P value of less than .05was considered statistically
significant.Heterogeneity between studieswas assessedwith
the CochranQ and I2 statistics. For the qualitative interpreta-
tion of heterogeneity, I2 values of at least 50% were consid-
ered to represent substantial heterogeneity,while values of at
least 75% indicated considerable heterogeneity per the Coch-
rane Handbook for Systematic Reviews of Interventions.13
Publication bias (ie, assessment of bias across studies) was
evaluated both graphically using a funnel plot14 andwith the
Egger statistical test.15
In the individual-patient database, we divided patients,
according to the CMB count in neuroimaging that was per-
formed prior to IVT, into 3 subgroups: (1) CMB absence (0
CMBs); (2) low/moderate CMB burden (1-10 CMBs); and
(3) high CMB burden (>10 CMBs). Continuous variables with a
normal distribution were described as mean (SD) and non-
normally distributed variables were described as median and
interquartile range (IQR), respectively. Categorical variables
were presented as percentages. All variables between the 3
different subgroups were compared by means of analysis of
variance or the Kruskal-Wallis test in variables with no evi-
dence of normal distribution. Statistical significance for all
tests was assumed if P < .05. Univariable and multivariable
analyses were performed using logistic regression to identify
predictors of sICH. Those factors that contributed to the out-
come in the initial univariable analyses at P values of less
than 0.1 were considered as candidate variables for themulti-
variable model. In the final multivariable analyses, statistical
significance was achieved if P was less than .05, calculated
by the likelihood ratio test. Associations in logistic regression
analysis were presented using odds ratios (ORs) with their
corresponding 95% CIs. We also performed again all univari-
able and multivariable analyses after dichotomizing the con-
tinuous variables according to the median value of their
corresponding distribution.
Pairwise meta-analyses were conducted using Review
Manager version 5.3 software (The Nordic Cochrane Centre,
The Cochrane Collaboration) and the Comprehensive Meta-
analysis version 2 software (Biostat). Individual-patient data
analysis was performed with the Stata Statistical Software
Release 13 for Windows (StataCorp LP).
Results
Study Selection and Study Characteristics
Systematic search of the Medline and Scopus databases
yielded 43 and 39 results, respectively. After removing dupli-
cates, the titles and abstracts from the remaining 57 studies
were screened, and 12 potentially eligible studies for the
meta-analysis were retained. After retrieving the full-text ver-
sion of the aforementioned 12 studies, 4 studies were
excluded because they reported treatment with intra-arterial
thrombolysis,16 mixed study population (treatment with
intra-arterial thrombolysis or IVT),17 no data on sICH rates,18
or MRI acquisition not solely before IVT administration.19 The
excluded studies with the corresponding reasons for exclu-
sion are presented in eTable 1 in the Supplement. In the final
presentation of the literature search results, there was no con-
flict or disagreement between the 2 reviewers, and the 8 stud-
ies that met the study protocol’s inclusion criteria,20-27
together with the data from our institution,10 were included
both in the qualitative and quantitative synthesis (eFigure 1 in
the Supplement). The authors of 1 study26 provided nonpub-
lished data regarding sICH incidence in the 4 CMB subgroups
that have been included in this meta-analysis.
The characteristics of the included studies, comprising a
total of 2479 patients, are summarized in eTable 2 in the
Supplement.All studyprotocolsprovided sICHevents accord-
ing to theEuropeanCooperativeAcute StrokeStudy–II (ECASS
II) definition (any intracranial bleed with ≥4 points worsen-
ing on the National Institutes of Health Stroke Scale score
within 7days).28 Thus,we selected theECASS II definitionbe-
cause this was the most common definition used across dif-
ferent centers. Only 2 of the study protocols used SWI for the
detection of CMBs prior to tissue plasminogen activator
administration,23,27 while the remaining 7 used the GRE
sequence.10,20-22,24-26 Similarly, 3-T MRI scans were per-
formed in2studyprotocols,20,27 1 researchgroup10,23usedboth
1.5- and 3-T MRI scans for pre-IVT screening, and 1.5-T MRI
scans were performed in the remaining 5 studies.21,22,24-26
PairwiseMeta-analyses
The risk of sICH after IVT was found to be higher in patients
with evidence of CMB presence when compared with pa-
tients without CMBs on MRI prethrombolysis screening (RR,
2.36; 95%CI, 1.21-4.61; P = .01; Figure 1). No evidence of sub-
stantial heterogeneity was found (I2 = 46%; P for Cochran Q
statistic, .06), while the visual inspection of the funnel plots
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(eFigure 2 in the Supplement) and the Egger statistical test
(P = .22) revealed no evidence of publication bias. More spe-
cifically, random-effects pooled incidence of sICH was 3.2%
(95% CI, 1.7%-6.1%) for patients with CMB absence and 6.9%
(95%CI, 5.1%-9.4%) for patientswith 1 ormore CMBs present
on pre-IVT MRI screening (eFigure 3 in the Supplement).
Theprevalenceof low/moderate (1-10CMBs) andhigh (>10
CMBs) CMBburdenwas 18.9% (n = 343) and0.8% (n = 15), re-
spectively, in the 5 studies that reported CMB count on base-
line neuroimaging. An even higher risk for sICH after IVTwas
found in thosepatientswithevidenceofhighCMBburden (>10
CMBs) when compared with both patients with 0 to 10 CMBs
(RR, 12.10; 95%CI, 4.36-33.57;P < .001;Figure 2A) and 1 to 10
CMBs (RR, 7.01; 95% CI, 3.20-15.38; P < .001; Figure 2B). No
evidenceofheterogeneitywas found inbothanalyses (I2<50%,
P for CochranQ statistic >.10). The random-effects pooled in-
cidenceof sICHwas6.4%(95%CI,4.2%-9.5%) forpatientswith
1 to10CMBsand46.9%(95%CI,22.8%-72.5%) forpatientswith
more than 10 CMBs on pre-IVT screening (eFigure 4 in the
Supplement).
In subgroup analyses, no differences were found when
studieswere stratified according to the imagingprotocol used
for the detection of CMBs in the MRI scan (GRE vs SWI; eFig-
ures 5-7 in the Supplement) performed prior to the adminis-
tration of IVT. The higher field strength (3 T) of the MRI scan
was associated with a higher risk of sICH in patients with 1 or
more CMBs in comparison with patients without CMB (RR,
5.90; 95%CI, 2.13-16.33;P < .001), but this associationdidnot
reachstatistical significance (P = .29) instudies includinga field
strength of 1.5 T (RR, 1.42; 95% CI, 0.74-2.72; P = .02 for sub-
groupdifferencesbetweenstudiesusing3-and1.5-TMRI;eFig-
ure 8 in the Supplement). However, in the subgroup analyses
evaluating the risk of sICH in patients with high CMB burden
(>10 CMBs) in comparisonwith the groupswith 1 to 10 or 0 to
10CMBs,noheterogeneitywasdetectedbetweenstudieswith
3-Tand thosewith 1.5-TMRI imagingprotocols (eFigures9and
10 in the Supplement).
The exclusion of our pilot study10 that has been pub-
lished only as an abstract did not alter the reported associa-
tions between high CMB count and risk of sICH in patients
with AIS treated with IVT (eTable 3 in the Supplement): RR
for more than 10 CMBs vs 0 to 10 CMBs = 10.41 (95% CI, 3.20-
33.87) and RR for more than 10 CMBs vs 1 to 10 CMBs = 7.32
(95% CI, 3.21-16.65).
Meta-analysis of Individual-Patient Data
Togetherwithour single-centerdata,10 individual-patientdata
wereprovided fromthecorrespondingauthorsof2other study
protocols.20,23 Thebaseline characteristics of our studypopu-
lation (n = 521), stratified by the count of CMBs on pre-IVT
imaging, are presented in Table 1. The prevalence of low/
moderate (1-10 CMBs) and high (>10 CMBs) CMB burden was
21.9%(n = 114)and1.5%(n = 8), respectively, in thestudypopu-
lation of the individual-patient data meta-analysis. Patients
with high CMB burden (>10 CMBs) were older (P < .001) than
patients with low/moderate CMB burden and patients with
CMB absence, but did not differ from the other 2 groups in
terms of other baseline characteristics. The rates of sICH dif-
fered (P < .001) between the groups as follows: 2.2% (95%CI,
1.2%-4.3%) in patients with 0 CMBs, 6.1% (95% CI, 3.0%-
12.3%) inpatientswith 1 to 10CMBs,and50.0%(95%CI,21.5%-
78.5%) in patients with more than 10 CMBs on pretreatment
MRI scan. A total of 7 patients (35% of all patients with sICH)
had evidence of CMB on pretreatment MRI located in the
same area where symptomatic intracranial bleeding
occurred following IVT.
In the individual-patient data meta-analysis, high CMB
burden (>10 CMBs) was associated with increased likelihood
of sICH in comparison with the reference group of 0 to 10
CMBs before (unadjusted OR, 31.06; 95% CI, 7.12-135.44;
P < .001) and after adjusting (adjusted OR, 18.17; 95% CI,
2.39-138.22; P = .005) for potential confounders (demo-
graphics, vascular risk factors, baseline stroke severity, pre-
treatment serum glucose, onset-to-treatment time, MRI field
Figure 1. Forest Plot Comparing the Risk of Symptomatic Intracranial Hemorrhage Following Intravenous Thrombolysis In Patients
With Acute Ischemic StrokeWith andWithout Cerebral Microbleeds (CMBs) on PretreatmentMagnetic Resonance Imaging
Weight,
%
Favors
CMB Presence
Favors
CMB Absence
RR Intravenous, Random, (95% CI)
0.01 101.0 100 10000.1
CMB Present
Events Total
CMB Absent
Events TotalStudy or Subgroup
RR Intravenous,
Random, (95% CI)
13.37 81 3 245Dannenberg et al20 7.06 (1.87-26.66)
6.61 8 2 36Derex et al21 2.25 (0.23-21.89)
17.15 86 13 484Fiehler et al22 2.16 (0.79-5.92)
4.21 3 0 18Goyal et al10 14.25 (0.70-290.12)
10.32 38 4 136Gratz et al23 1.79 (0.34-9.40)
Test for overall effect: Z = 2.52 (P = .01) 
Heterogeneity:  τ2 = 0.42; χ2 = 14.79, df = 8 (P = .06); I2 = 46%
4.70 11 5 59Kakuda et al24 0.45 (0.03-7.69)
10.24 72 2 152Kimura et al25 4.22 (0.79-22.52)
22.812 150 52 567Turc et al26 0.87 (0.48-1.59)
10.96 132
581
2 201Yan et al27 4.57 (0.94-22.29)
100.01898Total (95% CI) 2.36 (1.21-4.61)
38 83Total events
RR indicates risk ratio.
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strength, and MRI sequence) in logistic regression models
(Table 2). The former association persisted in the subgroup
of patients with presence of CMB on pretreatment MRI.
More specifically, high CMB burden (>10 CMB) was associ-
ated with higher likelihood of sICH in comparison with low/
moderate CMB burden (1-10 CMBs) in univariable (un-
adjusted OR, 3.91; 95% CI, 1.77-8.63; P = .001) and mul-
tivariable (adjusted OR, 3.15; 95% CI, 1.13-8.73; P = .03) logis-
tic regression analyses (Table 3).
In additional analyses, CMB presence was independently
associated with an increased risk of sICH after IVT (OR, 3.28;
95% CI, 1.07-10.06; P = .04), after adjusting for potential con-
founders in multivariable logistic regression. However, we
detected no association between CMB numbers entered as a
Figure 2. Forest Plots Comparing the Risk of Symptomatic Intracranial Hemorrhage Following Intravenous Thrombolysis in Patients
With Acute Ischemic StrokeWith Evidence of Cerebral Microbleed (CMB) Burden (>10 CMBs)
Weight,
%
Favors
CMB Burden (+)
Favors
CMB Burden (–)
RR Intravenous, Random, (95% CI)
101.0 1000.1
>10 CMBs
Events Total
1-10 CMBs
Events TotalStudy or Subgroup
RR Intravenous,
Random, (95% CI)
43.43 5 4 76Dannenberg et al20 11.40 (3.46-37.57)
21.81 2 4 84Fiehler et al22 10.50 (1.95-56.56)
8.81 1 0 2Goyal et al10 4.50 (0.32-63.94)
7.90 2 2 36Gratz et al23 2.47 (0.15-40.53)
18.21 5 11 145Turc et al26 2.64 (0.42-16.65)
Test for overall effect: Z = 4.86 (P < .001) 
Heterogeneity:  τ2 = 0.00; χ2 = 2.58, df = 4 (P = .63); I2 = 0%
15 100.0343Total (95% CI) 7.01 (3.20-15.38)
6 21Total events
Patients with 1 to 10 CMBsA
Weight,
%
Favors
CMB Burden (+)
Favors
CMB Burden (–)
RR Intravenous, Random, (95% CI)
101.0 100 10000.1
>10 CMBs
Events Total
0-10 CMBs
Events TotalStudy or Subgroup
RR Intravenous,
Random, (95% CI)
33.53 5 7 321Dannenberg et al20 27.51 (9.88-76.62)
24.81 2 17 568Fiehler et al22 16.71 (3.87-72.14)
10.21 1 0 20Goyal et al10 31.50 (1.82-546.26)
11.50 2 6 172Gratz et al23 4.44 (0.32-62.18)
20.11 5 63 712Turc et al26 2.26 (0.39-13.25)
Test for overall effect: Z = 4.79 (P < .001) 
Heterogeneity:  τ2 = 0.54; χ2 = 6.84, df = 4 (P = .14); I2 = 41%
15 100.01793Total (95% CI) 12.10 (4.36-33.57)
6 93Total events
Patients with 0 to 10 CMBsB
A, Compared with patients with 1 to 10 CMBs. B, Patients with 0 to 10 CMBs on pretreatment magnetic resonance imaging. RR indicates risk ratio.
Table 1. Baseline Characteristics of Patients Included in the Individual-Patient DataMeta-analysis
Cerebral Microbleeds
P ValueNοne 1-10 >10
Patients, No. 399 114 8
Age, mean (SD), y 70.7 (13.3) 77.7 (10.1) 83.1 (7.6) <.001
Male, No. (%) 179 (44.9) 51 (44.7) 4 (50.0) .96
NIHSS score at admission, median (IQR) 7 (4-13) 8 (5-14) 8.5 (8-12.5) .52
HTN, No. (%) 312 (78.2) 99 (86.8) 7 (87.5) .11
AF, No. (%) 144 (36.2) 51 (44.7) 2 (25) .26
DM, No. (%) 81 (20.3) 31 (27.2) 1 (12.5) .24
Smoking, No. (%) 74 (18.6) 16 (14.0) 1 (12.5) .34
CAD, No. (%) 71 (17.9) 21 (18.4) 3 (37.5) .46
OTT, mean (SD), min 161.7 (63.5) 159.0 (58.7) 151.5 (29.7) .87
Glucose level, mean (SD), mg/dL 130.2 (41.6) 131.9 (42.4) 117.8 (28.2) .67
sICH, No. (%) [95% CI] 9 (2.2)
[1.2-4.3]
7 (6.1)
[3.0-12.3]
4 (50.0)
[21.5-78.5]
<.001
Abbreviations: AF, atrial fibrillation;
CAD, coronary artery disease;
DM, diabetes mellitus;
HTN, hypertension; IQR, interquartile
range; NIHSS, National Institutes of
Health Stroke Scale;
OTT, onset-to-treatment time;
sICH, symptomatic intracerebral
hemorrhage.
SI conversion factor: To convert
glucose tomillimoles per liter,
multiply by 0.0555.
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continuous variable in the logistic regression models and risk
of sICH in patients with AIS with 1 or more CMB on pretreat-
ment MRI (OR per 1-CMB increase, 1.00; 95% CI, 0.99-1.02;
P = .79). Similarly, no significant association was detected
between location of CMB (cortical vs subcortical) and the risk
of sICH in patients with AIS treated with IVT in initial univari-
able logistic regression analyses (OR, 1.41; 95% CI, 0.35-5.62;
Table 3).
Discussion
Our pairwise and individual-patient data meta-analyses
showed that high CMB burden (>10 CMBs) on pretreatment
MRI was independently associated with sICH risk in patients
with AIS treated with IVT. High CMB burden was only more
prevalent in older patients and was not associated with
other risk factors. We consistently detected an increased
incidence of sICH in this subgroup in comparison with the
subgroups with CMB absence or low/moderate CMB burden
on pretreatment MRI. More specifically, high CMB burden
was related to a 3-fold and 7-fold increase in the risk of sICH
in comparison with AIS with low/moderate CMB burden
(1-10 CMBs) in the individual patient data and the pairwise
meta-analyses, respectively. The excessive sICH rate (50.0%
[95% CI, 21.5%-78.5%] in the individual-patient data and
46.9% [95% CI, 22.8%-72.5%] in the pairwise meta-analyses)
in the subgroup of patients with AIS with high CMB burden,
when combined with the low prevalence of high CMB bur-
den (1.5%) among consecutive patients with AIS treated with
IVT, indicate that systemic thrombolysis should be adminis-
tered with extreme caution in this AIS subgroup and necessi-
tate the inclusion of CMB burden in individual risk stratifica-
tion scores predicting the likelihood of postthrombolysis
sICH. Finally, our pairwise meta-analysis indicated that CMB
presence on pretreatment MRI was associated with an
approximately 2-fold higher likelihood of sICH in patients
with AIS treated with IVT.
Table 2. Univariable andMultivariable Logistic Regression on the Risk of Symptomatic Intracerebral
Hemorrhage in the Patients Included in the Individual-PatientMeta-analysis
Univariable Analysis
OR (95% CI) P Value
Multivariable Analysis
OR (95% CI) P Value
Age, per 1-y increase 1.06 (1.02-1.11) .007 1.05 (0.99-1.12) .10
Male sex 1.88 (0.76-4.69) .17 NA NA
NIHSS score at admission,
per 1-point increase
1.01 (0.94-1.08) .80 NA NA
HTN 1.41 (0.41-4.92) .59 NA NA
AF 2.42 (0.90-6.46) .08 2.35 (0.70-7.92) .17
DM 1.21 (0.43-3.40) .72 NA NA
Smoking 1.18 (0.38-3.62) .77 NA NA
CAD 0.80 (0.17-3.70) .76 NA NA
OTT, per 1-min increase 1.01 (0.99-1.01) .05 1.01 (1.00-1.02) .03
Glucose level 1.00 (0.99-1.01) .97 NA NA
High CMB burdena 31.06 (7.12-135.44) <.001 18.17 (2.39-138.22) .005
SWI 0.85 (0.32-2.25) .74 NA NA
3-T MRI 1.11 (0.44-2.84) .82 NA NA
Abbreviations: AF, atrial fibrillation;
CAD, coronary artery disease;
CMB, cerebral microbleed;
DM, diabetes mellitus;
HTN, hypertension; MRI, magnetic
resonance imaging; NA, not available;
NIHSS, National Institutes of Health
Stroke Scale; OR, odds ratio;
OTT, onset-to-treatment time;
SWI, susceptibility-weighted imaging.
a More than 10 CMBs onMRI.
Table 3. Univariable andMultivariable Logistic Regression Analysis in PatientsWhoHave Evidence
of CMB Presence Prior to IVT Administration
Univariable Analysis
OR (95% CI) P Value
Multivariable Analysis
OR (95% CI) P Value
Age 1.03 (0.96-1.10) .40 NA NA
Male sex 3.63 (0.91-14.42) .07 5.33 (0.97-29.19) .05
NIHSS score at admission 0.97 (0.87-1.09) .65 NA NA
HTN 0.35 (0.08-1.50) .16 NA NA
AF 2.08 (0.55-7.81) .28 NA NA
DM 0.60 (0.12-2.93) .53 NA NA
Smoking 2.60 (0.61-10.97) .19 NA NA
CAD 0.55 (0.06-4.84) .59 NA NA
OTT 1.01 (0.99-1.02) .08 1.01 (0.99-1.02) .062
Glucose level 0.99 (0.97-1.01) .48 NA NA
High CMB burdena 3.91 (1.77-8.63) .001 3.15 (1.13-8.73) .03
Cortical CMB presence 1.41 (0.35-5.62) .63 NA NA
SWI 0.46 (0.09-2.25) .34 NA NA
3-T MRI 1.39 (0.35-5.54) .64 NA NA
Abbreviations: AF, atrial fibrillation;
CAD, coronary artery disease;
CMB, cerebral microbleed;
DM, diabetes mellitus;
HTN, hypertension; IVT; intravenous
thrombolysis; NA, not available;
NIHSS, National Institutes of Health
Stroke Scale; OR, odds ratio;
OTT, onset-to-treatment time;
SWI, susceptibility-weighted imaging.
a More than 10 CMBs onMRI.
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Ourfindingsare in linewiththepreviouslypublishedmeta-
analyseson this topic,whichboth suggestedan increase in the
riskofpostthrombolysis sICH in thepresenceofCMBs.5,6How-
ever, toourknowledge,our studywas the first tohighlight that
the aforementioned risk is significantly more pronounced in
patientswithahighCMBburden.Moreover,we includedmore
patients inourpairwisemeta-analysis (2479patientswithAIS)
compared with the prior studies (790 patients with AIS5 and
2028 patients with AIS,6 respectively) and performed an in-
dividual-patient data meta-analysis using original data from
available studies.
Cerebralmicrobleeds are not only highly prevalent in pa-
tients with cerebrovascular disease but also constitute an in-
dependent risk factor for stroke.29 Moreover, there seems to
be a common link between cerebral ischemia/hemorrhage,
Alzheimer disease, cerebral amyloid angiopathy, and vascu-
lardementia.30Results fromtheFraminghamHeart StudyOff-
spring and Cohort study suggest that the overall prevalence
of CMBs in the community is low (4.7%). However, signifi-
cantlyhigherprevalence rates areobservedwithadvancedage
andmale sex.31 In another cohort study, a nearly 7-fold differ-
ence in the prevalence rate of CMB was observed among
middle-aged persons aged 45 to 50 years (6.5%) and persons
80 years or older (35.7%).32 The increased incidence of CMBs
with agepresumably reflects the cumulative effect of bothhy-
pertension and cerebral amyloid angiopathy on cerebral vas-
culatureduringageprogression.33Theoccurrenceof thesemi-
crobleeds maymanifest as either the result of a hemorrhagic
infarction/microinfarction or an isolated interruption of vas-
cular integrity.30Postmortemanatomical findings indicate that
CMBs found in elderly patients occur at the capillary level, in-
dependently of both amyloid deposition at the CMB site and
the history of hypertension.34 In terms of pathophysiology,
cortical CMBs in elderly individuals with no cognitive defi-
cits were found to be associated with widespread chronic
hypoperfusion and increased risk of neuronal injury and
neurodegeneration.35
Extensive cerebral small-vesseldiseasemayconstitute the
intermediate link between CMB burden and excessive risk of
sICH following systemic thrombolysis for AIS. This is sup-
ported by the fact that increasing leukoaraiosis, another neu-
roimaging marker of cerebral small-vessel disease, has also
been associatedwith ahigher risk of sICH inpatientswithAIS
treatedwith IVT.36 Inaddition,higher ratesof spontaneous ICH
have been observed in cardiovascular patients with CMBs
treatedwithaspirin.37Consequently, itmaybepostulated that
small-vessel disease (including cerebral amyloid angiopathy
and hypertensive arteriopathy) can cause weakening and
fragility of blood vessel walls and subsequently lower the
threshold for postthrombolysis sICH in patients with AIS.7
Cross-sectional study data from cognitively normal indi-
viduals suggest that cortical CMBs could be related to chronic
hypoperfusion and increased risk for neuronal injury.35 How-
ever, no significant differenceswere found in the rates of ana-
tomical CMB distribution (cortical vs subcortical) in a cohort
study of patients with primary ICH.38 In addition, our indi-
vidual-patientdatameta-analysis indicatedthat theriskofsICH
in patients with AIS treated with IVT did not differ on the ba-
sis of CMB location (cortical vs subcortical).Nevertheless, this
specific research question deservers further investigation in
larger, prospective registries.
Several limitations of this study need to be acknowl-
edged. First, only 5 studies (comprising 1808 patients) of the
9 total included studies (comprising 2479 patients) reported
data on the risk of symptomatic intracranial hemorrhage fol-
lowing IVT inpatientswithAIS according toCMBcount strati-
fication (Figure 2). Moreover, from the 9 study protocols that
were included in the pairwise analysis, only 3 provided indi-
vidual-patient data onour request for further analyses.10,20,23
The aforementioned 3 study protocols included in the indi-
vidual-patientanalysis comprised21%of the totalpatients that
were included in the pairwise analysis. However, we should
underline that the findings of the individual-patient analysis
werepractically identical to thoseof thepairwiseanalysis, sug-
gesting true representativeness of the total population and a
lowriskof selectionbias. Second, in the individual-patientdata
meta-analysis only, 8 patients had high CMB burden (>10
CMBs). Even though the number is relatively small, the find-
ing of the excessively high sICH risk in this subgroupwas also
present in thepairwisemeta-analysis (including 5 studies and
15 patients with >10 CMBs) with no evidence of heteroge-
neity among studies (Figure 2), indicating that the aforemen-
tioned association is not owing to a play of chance.
Third, as evident from eTable 2 in the Supplement, some
of thebaseline characteristicswerenot available in3of9 study
protocols.21,22,27However, nearly all studies provideddata on
age, sex,National InstitutesofHealthStrokeScale scoreonad-
mission, and onset-to-treatment time. Moreover, we should
acknowledge thatdataonbloodpressure control following in-
travenous tissueplasminogenactivator infusionwerenotavail-
able in most study protocols. This could be another impor-
tant limitation because it may be safer to treat patients with
CMBonpre-IVTMRI scanwhenexquisite bloodpressure con-
trol is provided.35,39 Another potential limitation is that data
concerning antithrombotic medication taken before admis-
sion are lacking; thus, the possible interaction between daily
intake of aspirin andCMBs regarding the risk of post-IVT sICH
cannot be evaluated. In addition, our analysis did not inves-
tigate the association between the anatomical distribution or
size of CMBs and risk of sICH.40,41 Another important limita-
tion of our study protocol is that we cannot exclude the hem-
orrhagic transformation of cerebral infarction as the cause of
anewhematomacausing clinical deterioration, and thisneeds
to be taken into accountwhen interpreting our findings.More
specifically, ECASS-II criteria that were used for the defini-
tionof sICH include intra-infarctparenchymalhematoma type
2owing tohemorrhagic transformation.28Even though the tis-
sue plasminogen activator–mediated bleed into the infarct is
not a CMB, our data still indicate that high CMB burden (CMB
count >10) is associated with an increased risk for intracra-
nial bleeding, even at sites remote to any CMB and only into
the infarct. Therefore, it cannot be ruled out that the re-
ported sICH are the concurrence of 3 varying kinds of bleed-
ing, ie, parenchymal hematoma type 2 in the infarct but out-
side the CMB, parenchymal hematoma type 2 remote in the
CMB but outside the infarct, or parenchymal hematoma type
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2 remotebothoutside the infarct andoutside theCMB.Fourth,
weshouldemphasize thatour findingsapply toa limitednum-
ber of patients with AIS who undergo MRI prior to treatment
with intravenous tissue plasminogen activator. Patients un-
dergoing MRI (in contrast to computed tomography) are less
severely ill, lessoftendisorientatedoragitated,anddonothave
cardiac pacemakers.42
Regarding the imaging method used for the detection of
CMBs on MRI scan, SWI is considered to be more sensitive for
CMB detection compared with GRE T2*.43,44 However, the
higher sensitivity of SWI was not related to higher clinical rel-
evance in terms of vascular risk factors and/or radiologic
markers of small-vessel disease.44 Of the 9 included studies in
our meta-analysis, only 2 used SWI for CMB detection prior to
the administration of IVT.23,27 In the subgroup analyses that
we performed according to the imaging protocol used for the
detection of CMBs, no significant differences were found
among the studies that used SWI and those that screened
patients with GRE.
Furthermore, in the subgroup analysis according to the
strength of the magnetic field used in the study protocols,
only the 3-T MRI studies showed consistently significant
increased risk of sICHwith high CMB count (eFigures 9 and 10
in the Supplement), while the former association was signifi-
cant in 1 (eFigure 9 in the Supplement) of 2 subgroup analyses
including only 1.5-T MRI studies. However, the threshold of
statistical significance was barely missed (P = .09) in the
remaining subgroup analysis, including only 1.5-T MRI (eFig-
ure 10 in the Supplement), and this may be because of the
limited sample size and small number of included studies
(n = 2), resulting in the wide 95% CI of reported associations.
Moreover, susceptibility artifacts increase with the main mag-
netic field strength, but are only slightly larger at 3-T com-
pared with standard 1.5-T MRI. This may be helpful in visual-
ization but most likely does not change the number of
visualized CMBs.45,46 On the other hand, detection bias can-
not be reliably excluded in the present analyses. Because
higher-field MRIs and the use of SWI are known to increase
CMB detection, some patients with CMB absence could be
shifted to the low/moderate or high CMB burden categories if
SWI and/or higher-field protocols were used. Because of this
specific limitation and the small number of available studies,
we consider that our analyses have a very limited power to
detect a possible modifying effect according to theMRI proto-
col used.
Conclusions
Our findings suggest that CMB burden is an independent risk
factor that may augment the risk of sICH in patients with AIS
treated exclusively with systemic thrombolysis. These
observations imply that CMB burden may be included in
individual risk stratification predicting the risk of sICH fol-
lowing IVT for AIS. The challenge remains in identifying
CMB burden without MRI in the setting of AIS management
where only a noncontrast computed tomography is standard
of care.
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